BRAF and melanoma: Notably, pharmacological BRAF inhibition further stimulated ERBB3 signaling in YAP1-activated melanoma cells in line with a previous report [46], highlighting ERBB3 as a particularly relevant target in MAPKi-resistant melanoma cells with high YAP1 activity.